Back to Subject Index | Return to Arthritis & Rheumatism Table of Contents Page

A protein, MHC class II genes, anti-U1 snRNP antibody and, 396
A1 receptor antagonist 8-cyclopentyl-dipropylxanthine, antiinflammatory mechanism of adenosine regulators and, 1040
A2 protein, autoimmune response to the spliceosome and, 777
AA amyloidosis, RA and, nephrotic syndrome and azathioprine in, 1851
AA chain homodimer, chondrocytes in aging and development and, 960
Abdomen
pain in, in NSAID-induced gastroduodenal injury in children, 1225
ultrasonography of, 736
Abscess, brain, mimicking giant cell arteritis, 1710
Absorptiometry, dual-energy x-ray, 61, 334, 806, 902, 1204
Absorption
HRES-1 antibodies and, in SLE and overlap syndromes, 1660
immunosuppressive drugs during pregnancy and, 1722
Absorption spectroscopy, ultraviolet, to study elastin and collagen degradation in SSc, 517
Academic medicine, rheumatology and, 451
Acanthosis nigricans, 862
Accessory factor, cytokines, early response genes and, 877
Acetaminophen, analgesic, guidelines for medical management of OA and, 1535, 1541
Achilles tendon, joint and connective tissue ultrasonography of, 736
Acid-fast bacilli, in tuberculous and foreign-body granulomatous reactions in a total knee prosthesis, 1325
Acne, dehydroepiandrosterone in SLE and, 1826
Acquired immunodeficiency syndrome (AIDS)
gouty arthritis in, 570
HRES-1 antibodies and, in SLE and overlap syndromes, 1660
RA and, 1701
Activation markers, in RA synovial membrane, 1346
Active inflammation, HLA antigens in disease progression in psoriatic arthritis and, 845
Active juvenile DM, enteroviral RNA, bacterial DNA and, 1513
Active RA
AIDS and, 1701
azathioprine and MTX in, 1799
EDA-containing fibronectin in synovium in, 678
leflunomide in, 1595
MRI and PET in, 819
prednisone vs chloroquine in, 334
refractory, CAMPATH-1H in, 1187, 1589
tenidap and piroxicam in, 29
Active SLE, IL-1 receptor antagonist in, 1055
Activities of daily living, guidelines for medical management of OA and, 1535, 1541
Acute anterior uveitis, HLA-DR8 in, in AS, 547
Acute antiinflammatory effects, of adenosine regulators, 1040
Acute diffuse neurologic involvement, in spin-spin relaxation of brain tissue in SLE, 810
Acute disability, in social and psychological impact of musculoskeletal conditions, 1351
Acute exacerbation of pain, in guidelines for medical management of OA, 1535
Acute infection, in pathogenesis of spondylarthropathies, 1547
Acute infusion toxicity, CAMPATH-1H in refractory RA and, 1589
Acute interstitial nephritis, renal biopsy in RA and, 242
Acute interstitial pneumonia, due to cytomegalovirus after low-dose MTX in RA, 291, 1528
Acute Kawasaki disease, autoimmune disease induction by microbial pathogens and, 458
Acute parvovirus B19-induced pancytopenia, MTX in RA and, 1023
Acute-phase protein, in RA, 29, 642, 1447
Acute-phase reactants, in RA, 642, 727
Acute posterior multifocal placoid pigment epitheliopathy, in systemic JRA, 446
Acute respiratory failure, in antineutrophil cytoplasmic antibody pulmonary capilaritis with circulating primed neutrophils, 1855
Acute synovial inflammation, quantification of, by MRI, in RA, 1610
Acute trauma, glycosaminoglycan epitopes in knee joint fluid after, 953
Adenosine regulators, antiinflammatory mechanism of, 1040
Adherent cells, RF-secreting B cells in RA and, 1771
Adherent IgG, IL-1 receptor antagonist in SLE and, 1055
Adhesin YadA, Yersinia enterocolitica, binding of, to collagen, 1283
Adhesion, rheumatoid synovial fibroblast, in human articular cartilage, 1694
Adhesion molecules
Arg-Gly-Asp (RGD) peptide, IL-1 and, in chondrocyte metalloproteinase synthesis, 1304
ICAM-1, 184
immunosuppressive drugs during pregnancy and, 1722
in Lyme borreliosis, 565
in RA, 740, 1457
soluble, disease activity in SSc and, 184
VCAM-1, 184, 565
Adhesion neutrophils, antineutrophil cytoplasmic antibodies in mice and, 1375
Adipose tissue, in scleroderma in Tsk2 mouse, 1791
Adjuvant, Freund's complete, collagen type II in antigen-induced arthritis and, 1092
Adjuvant arthritis
radiography changes measured by quantitative image analysis, 129
in rats, 699, 1777
Adolescent medicine
acute posterior multifocal placoid pigment epitheliopathy in JRA, 446
chondrocytes in aging and development, 960
complement C4 deficiency in glomerulonephritis, 1333
factors affecting bone mass, 61
joint and connective tissue ultrasonography in, 736
Lyme arthritis in Europe, 361
Adrenocorticotropic hormone, NSAID and, 723
Adsorption, solid-phase, to study nucleosome-restricted antibodies in SLE and, 1485
Adult respiratory distress syndrome, anti-Jo-1 antibody in PM and, 1519
Adverse reactions
corticosteroids, pulse cyclophosphamide, plasma exchange and, in polyarteritis nodosa and Churg-Strauss syndrome, 1638
dehydroepiandrosterone in SLE and, 1826
draft guidelines for drugs in JRA clinical trials and, 715
guidelines for medical management of OA and, 1535
immunosuppressive drugs during pregnancy and, 1722
NSAID, gastrointestinal tract and, 5
in RA, 1177, 1187, 1447, 1589, 1595, 1799
in SSc, guidelines for clinical trials and, 351
sulfasalazine in spondylarthropathy and, 618
tenidap and, 1447
to tiludronate and etidronate in Paget's disease of bone, 851
Aerobic conditiong exercises, guidelines for medical management of OA and, 1535, 1541
Affective fatigue, in SLE, 826
Affinity, low, Fcγ receptor IIa in renal disease in SLE and, 1832
Affinity purification, to study MI-2 autoantigen in DM and, 1389
Agarose beads, HRES-1 antibodies and, in SLE and overlap syndromes, 1660
Agarose gel electrophoresis, to study apoptosis in RA synoviocytes, 485
Agarose-polyacrylamide gel electrophoresis
in RA, 525
to study proteoglycans in OA, 525, 660
Age
chondrocytes in aging and development and, 960
corticosteroids, pulse cyclophosphamide, plasma exchange and, in polyarteritis nodosa and Churg-Strauss syndrome, 1638
degenerative lumbar spinal stenosis and, 1236
elastin, collagen degradation and, in SSc, 517
enteroviral RNA, bacterial DNA and, in juvenile DM, 1513
epidemiology of polymyalgia rheumatica in Olmsted County, MN and, 369
erythrocytes in rheumatoid vasculitis and, 248
in fibromyalgia, 19, 161, 229, 235, 1218
infection, onset of giant cell arteritis and, 374
joint space measurement in hand radiographs using computerized image analysis and, 891
in OA, 799, 1134, 1500
in RA, 105, 601, 1031, 1120, 1204, 1630
risk factors for septic arthritis in joint disease and, 1819
in SLE, 274, 506, 551, 1260, 1492
T cell receptor Vβ gene in murine Sjogren's syndrome and, 1077
Aggrecan
core protein, 1678
in OA, 420, 525, 660
proteoglycans, in articular cartilage, 660
in RA, 660, 1031
stromelysin and, 1400, 1678
Aging, chondrocytes in, 960
Air pouch, murine, antiinflammatory mechanism of adenosine regulators and, 1040
Air spaces, in antineutrophil cytoplasmic antibody pulmonary capillaritis with circulating primed neutrophils, 1855
Ala, MHC class II genes, anti-U1 snRNP antibody and, 396
Albumin
in amyloidosis, 1851
in RA, 1194, 1851
serum, 164, 1092
Alcohol abuse, childhood sexual abuse, fibromyalgia and, 161, 229, 235
Alcohol use
factors affecting bone mass and, 61
NSAID, gastrointestinal tract and, 5
Alkaline phosphatase
in bone turnover and bone mass after estrogen, 292
in Paget's disease of bone, 851, 1506
in RA, 902
serum, 1506
Alkaline phosphatase-anti-alkaline phosphatase
to study granzyme A and perforin mRNA in RA synovium, 477
to study sacroiliitis in AS, 499
Allegheny County, Pennsylvania, incidence of SLE in, 1260
Alleles
Fcγ receptor, IgG receptors in autoimmune disease and, 306
HLA, 259, 396, 1660, 1715
HLA-DRB1*0404 allele and, gold-induced enterocolitis and, 755
HLA-DRB1*08, HLA-DR8, acute anterior uveitis and, in AS, 547
IL-1α polymorphism in JRA, 221
polyglot, polymorphism and, 1715
Alleles (cont'd)
shared-epitope DRB1, inheritance of HLA genes in RA and, 1754
in SLE, 110, 1832
TAP, Reiter's syndrome and, 684
typing for, autoantibodies in SSc in twins and, 1845
Allergic encephalomyelitis, experimental, autoimmune disease induction by microbial pathogens and, 458
Allergic reactions, to leflunomide in RA, 1595
Alloimmune reactions, IgG receptors in autoimmune disease and, 306
Allotypes, Fcγ receptor class IIa in renal disease in SLE and, 1832
Alopecia, reversible, leflunomide in RA and, 1595
α1 chain, cytokines, early response genes and, 877
α1-antitrypsin, end-stage liver disease, MTX and, 1014
α1(I) chain of type I collagen, Yersinia enterocolitica binding of adhesin YadA to, 1283
α1(I) procollagen mRNA, in scleroderma in Tsk2 mouse, 1791
αv integrin subunits, Arg-Gly-Asp (RGD) peptide, IL-1 and, in chondrocyte metalloproteinase synthesis, 1304
Alveolar damage, antineutrophil cytoplasmic antibody pulmonary capillaritis with circulating primed neutrophils, 1855
Alzheimer's disease, cognitive deficits in rheumatic diseases and, 1363
Ambulatory care, medical clinics, walking velocity in elderly in, 343
American Academy of Pediatrics, Committee on Drugs, 715
American Board of Internal Medicine, recertification program in rheumatology, 1169
American College of Physicians
Council of Subspecialty Societies, rheumatology and, 451
practice guidelines and, 1533
American College of Rheumatology (ACR)
A & R reader and author survey, 1019
Audiovisual Aids Subcommittee, 1733
Committee on Design and Outcomes in Clinical Trials in SSc, 351
Committee on Health Care Research, 727
Committee on Outcome Measures in RA Clinical Trials, 727
Committee for the Publication of A & R, 1019
criteria for SLE, 267, 872, 1475, 1832
Diagnostic and Therapeutic Criteria Committee, 722
outcome measures in RA clinical trials and, 1568
practice guidelines, 1533
preliminary definition of improvement in RA, 727
Presidential Address, 1994, 451
recommendations for liver biopsy after MTX in RA, 1115
Slide Competition, 1733
American Medical Association (AMA), rheumatology and, 451
American Rheumatism Association (ARA), criteria for SLE, 1475
Amino acids
DNA binding of IgM[gl] anti-DNA antibody and, 389
elastin and collagen degradation in SSc, 517
HRES-1 antibodies and, in SLE and overlap syndromes, 1660
human monoclonal antiphospholipid antibody and, 1068
MHC class II genes, anti-U1 snRNP antibody and, 396
p4 peptide binding to DRB1*0401 and, 1744
T cell receptors in RA and, 577
Yersinia enterocolitica binding of adhesin YadA to collagen and, 1283
Aminotransferase, asparate, liver biopsy after MTX in RA and, 1194
Amitriptyline, sleep electroencephalography and, in fibromyalgia, 1211
Amplification refractory mutation system-polymerase chain reaction, to study mannose-binding parotein gene polymorphism in SLE, 110
Amyloid A protein, serum, piroxicam, tenidap and, in RA, 29, 1447
Amyloidosis, RA and, 242, 1851
Amyopathic DM, MRI/MRS in, 68
Analgesic drugs
guidelines for medical management of OA and, 1535, 1541
hydroxychloroquine and pain, 445
NSAID, gastrointestinal tract and, 5
oral, 1541
topical, 1541
Anatomy, RA and, 315, 819
Anemia
in giant cell arteritis, 434
parvovirus B19 infection, chronic fatigue syndrome and, 638
sickle cell, bone marrow fat in inflammatory response to sickled erythrocytes and, 1349
Animal studies
See also Bovine, Canine, Mammalian, Monkey, Mouse, New Zealand white rabbits, Primate, Rabbit, Rat, Rhesus monkey, Tick, Tight skin 2 mouse
autoimmune disease induction by microbial pathogens, 458
collagen type II in antigen-induced arthritis, 1092
CPPD synovitis in rabbit OA, 201
immunosuppressive drugs during pregnancy and, 1722
in RA, IL-1 and TNFα in, 151
Ankle, joint
collagen type II in antigen-induced arthritis and, 1092
substance P and calcitonin gene-related peptide in rat adjuvant arthritis and, 699
Ankylosing spondylitis (AS)
histologic findings in sacroiliitis in, 499
HLA-B39 in, 1672
HLA-DR8 and acute anterior uveitis in, 547
juvenile, JRA and, 835
Klebsiella pneumoniae-reactive T cells in blood in, 1277
occurrence of, in twins in Finland, 381
pathogenesis of, 1547
Annular erythematous lesions, in cutaneous LE from photocopier ultraviolet emissions, 1152
Annular ligaments, in carpal tunnel syndrome due to T cell lymphomas, 1707
Anterior cruciate ligament
in experimental OA, 420, 525, 1290
transection of, 420
Anterior uveitis, acute, HLA-DR8 and, in AS, 547
Anti-A, U1 snRNP polypeptide antibodies, anti-U1 RNA antibodes in connective tissue disease and, 1837
Anti-A1, autoimmune response to the spliceosome and, 777
Anti-A2/RA33, autoimmune response to the spliceosome and, 777
Anti-anti-human antineutrophil cytoplasmic antibodies, antineutrophil cytoplasmic antibodies in mice and, 1375
Anti-B cell antibodies, granzyme A, perforin mRNA and, in RA synovium, 477
Antibiotics
Chlamydia trachomatis in synovial membranes and, 1410
in Lyme borreliosis, 565
in pediatric Lyme arthritis in Europe, 361
Antibodies
anti-A, U1 snRNP polypeptide, 1832
anti-A2/RA33, 777
anti-apolipoprotein A1, 1655
anti-B cell, 477
anticardiolipin, 115
anti-CD3, 649
anti-CD4, 1457, 1581, 1701
anti-CD20, 477
anti-CD45RO, 477
anti-CD56, 477
anti-CD68, 477
anti-DNA, 389
anti-dsDNA, 190, 1485
Antibodies (cont'd)
anti-E1α, 985
anti-ENA, 396
anti-Fas, 485
anti-52-kd, 990
anti-FVDIPEN, 1400
antiheterogeneous nRNP, 777
antihistone, 1024, 1485
anti-IL-1, 164
anti-La, 1271, 1418
anti-macrophage, 477
anti-Mi-2, 1389
anti-natural killer cell, 477
antineutrophil cytoplasmic, 306, 633, 1375, 1555, 1855
antinuclear, 1389, 1475, 1485, 1660
antiphosphatidylinositol, 115
antiphosphatidylserine, 115
antiphospholipid, 1068
anti-T cell, 477
anti-topoisomerase I, 1845
anti-type IV collagen, 477
anti-U1 RNA, 1837
anti-U1 RNP, 396
apolipoprotein A1, 1655
CAMPATH-1H, 1187, 1242
CD4, 1097
Chlamydia trachomatis in synovial membranes and, 1410
circulating, 1513
complement-fixing, 1513
cytoplasmic, 306, 633, 1375
in detection of stromelysin-cleaved rabbit aggrecan, 1400
HRES-1, 1660
HTLV-1, 690
IgG, 190, 361, 638, 985, 1418, 1513, 1832
IgM, 638, 985, 1513, 1832
in IL-1 in experimental arthritis in mice, 164
monoclonal, 115, 151, 164, 190, 254, 389, 506, 577, 649, 655, 669, 953, 1068, 1077, 1097, 1187, 1242, 1382, 1581, 1589, 1701, 1863
natural, autoimmunity and, 301
nucleosome-restricted, 1485
in OA, 660
polyclonal, 164
polypeptide, 1832
in RA, 96, 660, 678, 1771
Antibody-forming cells, in bone marrow transplantation in antiphospholipid syndrome, 115
Antibody-mediated T cells, T cell receptors, RA and, 1242
Antibody screening tests, Mi-2 autoantigen in DM and, 1389
Antibody staining, stromelysin degradation of cartilage and, 1678
Anti-C protein, MHC class II genes, anti-U1 snRNP antibody and, 396
Anti-CAMPATH-1H, CAMPATH-1H in refractory RA and, 1589
Anticardiolipin antibodies, monoclonal, in bone marrow transplantation in antiphospholipid syndrome, 115
Anticardiolipin autoantibodies, monoclonal, cross-reactivity of, with oxidized low-density lipoprotein, 1382
Anti-CD3
cytolytic activity of polyclonal T cells in SLE and, 506
IgG receptors in autoimmune disease and, 306
monoclonal antibodies, 506, 649
in RA, 381, 649, 946
Anti-CD4 monoclonal antibody
in AIDS, 1701
in RA, 1457, 1581, 1701
Anti-CD20 antibodies, anti-CD45RO antibodies, anti-CD56 antibodies, anti-CD68 antibodies, granzyme A, perforin mRNA and, in RA synovium, 477
Anticoagulant drugs, NSAID, gastrointestinal tract and, 4
Anticoagulants, lupus, human monoclonal antiphospholipid antibody and, 1068
Anticytokine drugs, IgG receptors in autoimmune disease and, 306
Anti-DNA antibody, binding of, immunoglobulin heavy chain in, 389
Anti-dsDNA antibodies
antigen-based heteropolymers and, 190
nucleosome-restricted antibodies in SLE and, 1485
Anti-E1α antibody, autoantibodies to pyruvate dehydrogenase in SSc and, 985
Anti-ENA antibodies, MHC class II genes, anti-U1 snRNP antibody and, 396
Anti-F response, SS-A/Ro 52-kd molecule epitopes and, 990
Anti-Fas antibodies, apoptosis, functional Fas antigen and, in RA synoviocytes, 485
Anti-Fcγ receptor autoantibodies, IgG receptors in autoimmune disease and, 306
Anti-52-kd SS-A/Ro autoantibodies, 990
Anti-FVDIPEN antibody, in detection of stromelysin-cleaved rabbit aggrecan, 1400
Antigen-binding surface, anti-apolipoprotein A1 in SLE and, 1655
Antigen-induced arthritis
collagen type II in, 1092
IL-1 and, 151, 164
Antigen-primed memory T cells, T cell receptors in RA and, 1242
Antigenemia, persistent, autoimmune disease induction by microbial pathogens and, 458
Antigenic epitopes, HRES-1 antibodies and, in SLE and overlap syndromes, 1660
Antigenic peptides, TAP alleles, Reiter's syndrome and, 684
Antigenicity, SS-A/Ro 52-kd molecule epitopes and, 990
Antigens
anti-ENA, antibodies, MHC class II genes, anti-U1 snRNP antibodies and, 396
anti-Sm and anti-U1 sn RNP, autoimmune response to the splicosome and, 777
arthritogenic, in pathogenesis of spondylarthropathies, 1547
bacterial, 458, 1277, 1547
Chlamydia trachomatis in synovial membranes and, 1410
elementary body, 1410
foreign, 458
heteropolymers, autoantibody clearance and, 190
HLA, in disease progression in psoriatic arthritis, 845
HLA-B39 and, in AS and JRA, 167
IgG, 1418
IgG receptors in autoimmune disease and, 306
IL-1 in experimental arthritis in mice and, 164
immunodominant, 1547
La, 1271, 1418
Lyme borreliosis and, 565
Mi-2 autoantigen in DM and, 123, 1389
microbial, 458
proliferating cell nuclear, in RA synovial membrane, 1346
in RA, 492, 577, 649, 1031, 1418, 1754
retroviral, 458
Ro, 990, 1271
self, 458, 477
Sm, HeLa cell, MHC class II genes, anti-U1 snRNP antibody and, 396
somatostatin in experimental arthritis and, 1687
super-, bacterial, autoimmune disease induction by microbial pathogens and, 458
surface, 1410
T cell receptor Vβ gene in murine Sjogren's syndrome and, 1077
TAP alleles, Reiter`s syndrome and, 684
tissue, 301, 458
Yersinia, 458
Antihistone antibodies
nucleosome-restricted antibodies in SLE and, 1485
pulmonary fibrosis and, in SSc, 1024
Anti-HRES-1, HRES-1 antibodies and, in SLE and overlap syndromes, 1660
Anti-human antineutrophil cytoplasmic antibodies, biology of, in mice, 1375
Anti-human apolipoprotein A1 autoantibodies, anti-apolipoprotein A1 in SLE and, 1655
Anti-IL-1
IL-1 in experimental arthritis in mice and, 164
in RA, 151
Anti-IL-6
IL-1 in experimental arthritis in mice and, 164
RF-secreting B cells in RA and, 1771
Anti-IL-10, RF-secreting B cells in RA and, 1771
Antiinflammatory drugs, FDA draft guidelines for, in JRA clinical trials, 715
Antiinflammatory mechanism, of adenosine regulators, 1040
Anti-Jo-1
antibody, adult respiratory distress syndrome and, 1519
PM and, 437, 1519
Anti-La
antibodies, 1271, 1418
HRES-1 antibodies and, in SLE and overlap syndromes, 1660
Antilymphocyte monoclonal antibody, humanized, CAMPATH-1H, in refractory RA, 1187, 1589
Anti-macrophage antibodies, granzyme A, perforin mRNA and, in RA synovium, 477
Anti-Mi-2 antibodies and autoantibodies, Mi-2 autoantigen in DM and, 123
Anti-MPO, antineutrophil cytoplasmic antibodies in SLE and, 633
Anti-natural killer cell antibodies, granzyme A, perforin mRNA and, in RA synovium, 477
Antineutrophil cytoplasmic antibodies
biology of, 1375
classic, 633
evaluative laboratory testing and, 1555
IgG receptors in autoimmune disease and, 306
perinuclear, 633
pulmonary capillaritis with circulating primed neutrophils and, 1855
in SLE, 633
Antinuclear antibodies
Mi-2 autoantigen in DM and, 1389
in SLE, 1475, 1485, 1660
Antinuclear autoantibodies, HRES-1 antibodies and, in SLE and overlap syndromes, 1660
Antinucleosome reactivity, nucleosome-restricted antibodies in SLE and, 1485
Antioxidants, lipoprotein oxidation in SSc and, 1060
Antiphosphatidylinositol antibodies, antiphosphatidylserine antibodies, in bone marrow transplantation in antiphospholipid syndrome, 115
Antiphospholipid antibody, human monoclonal 1068
Antiphospholipid syndrome
cross-reactivity of anticardiolipin autoantibodies with oxidized low-density lipoprotein and, 1382
experimental, transfer of, by bone marrow cell tranplantation, 115
human monoclonal antiphospholipid antibody in, 1068
primary, HLA-DR5 and DRB1*1204 in, 1340
Anti-PM-Scl, autoantibodies in SSc in twins and, 1845
Anti-PR3, antineutrophil cytoplasmic antibodies in SLE and, 633
Anti-pyruvate dehydrogenase complex antibodies, in SSc, 985
Antirheumatic drugs
cytolytic activity of polyclonal T cells in SLE and, 506
FDA draft guideline for, in JRA clinical trials, 715
in RA, 242, 819, 1447
Anti-RNP
anti-U1 RNA antibodies in connective tissue disease and, 1837
HRES-1 antibodies and, in SLE and overlap syndromes, 1660
Anti-Ro
antibodies, Ro and La antigens in human skin and, 1271
HRES-1 antibodies and, in SLE and overlap syndromes, 1660
positive sera, SS-A/Ro 52-kd epitopes and, 990
Anti-self immune response, autoimmune disease induction by microbial pathogens and, 458
Antisera, monospecific, Ro and La antigens in human skin and, 1271
Anti-70K
anti-U1 RNA antibodies in connective tissue disease and, 1837
reactivity, MHC class II genes, anti-U1 snRNP antibody and, 396
Anti-Sm, autoimmune response to the spliceosome and, 777
Anti-snRNP antigens, autoimmune response to the spliceosome and, 777
Anti-synovial antigens, in early RA, 1418
Anti-T cell antibodies, granzyme A, perforin mRNA and, in RA synovium, 477
Anti-threonyl transfer RNA synthetase, autoantibodies in SSc in twins and, 1845
Anti-TNF, IL-1 in experimental arthritis in mice and, 164
Anti-topoisomerase I antibodies, autoantibodies in SSc in twins and, 1845
Anti-218-kd Mi-2 autoantibodies, Mi-2 autoantigen in DM and, 1389
Anti-type IV collagen antibodies, granzyme A, perforin mRNA and, in RA synovium, 477
Anti-U1 RNA
antibodies, in connective tissue disease, 1837
HLA type in MCTD and, 259
Anti-U1 RNP
antibody, MHC class II genes and, 396
HLA type in MCTD and, 259
Anti-U1 snRNP
autoantibody, MHC class II genes, anti-U1 snRNP antibody and, 396
autoimmune response to the spliceosome and, 777
Anti-VDIPEN, stromelysin degradation of cartilage and, 1678
AP-1 transcription factor family, nuclear factor-κB in rheumatoid synovium and, 1762
Apolipoprotein A1, in SLE, 1655
Apoptosis, functional Fas antigen and, in RA synoviocytes, 485
Appendicular skeleton, monoclonal antibodies in detection of biochemical markers of arthritis and, 655
Arachidonate, nitric oxide and lipoxin A4 in polymorphonuclear cell vascular cytotoxicity and, 768
Arachidonic acid, NSAID, gastrointestinal tract and, 5
Arend, William P., new editor, Arthritis & Rheumatism, 890
Arg
HRES-1 antibodies and, in SLE and overlap syndromes, 1660
MHC class II genes, anti-U1 snRNP antibody and, 396
Arg-Arg-Glu, HRES-1 antibodies and, in SLE and overlap syndromes, 1660
Arg-Gly-Asp (RGD) peptide, IL-1 and, in chondrocyte metalloproteinase synthesis, 1304
Arginine
MHC class II genes, anti-U1 snRNP antibody and, 396
nitric oxide and lipoxin A4 in polymorphonuclear cell vascular cytotoxicity and, 768
Arm, cardiovascular fitness in end-stage OA and, 799
Arteries
pulmonary, in fatal pulmonary vasculitis in lupus pregnancy, 710
in Raynaud's phenomenon and scleroderma, 1
Arterioles, pulmonary, in fatal pulmonary vasculitis in lupus pregnancy, 710
Arteritis
cranial, anemia in, 434
giant cell, 374, 434, 939, 1710, 1722, 1733
temporal, 374, 434, 1710
Arthralgia
in atrial myxoma and cutaneous PAN with Crohn's disease, 1161
in pediatric Lyme arthritis in Europe, 361
in SLE, 1475
Arthritides, monoclonal antibodies in detection of biochemical markers of, 655
Arthritis
adjuvant, 129, 699, 1777
antigen-induced, 151, 164, 1092
Arthritis Knowledge Questionnaire and, 590
bacterial cell wall-induced, 458
chronic, 361, 458, 1410, 1687
collagen, 151
deforming, 259
diagnosis of, 449
early, 1410
erosive, 259
experimental, 129, 164, 458, 1687
gouty, 570, 1241
incidence of, 451
inflammatory, 151, 458, 873
Lyme, 361, 461, 458, 565
monoclonal antibodies in detecting biochemical markers of, 655
murine, 164
mycobacterial, 13
pauciarticular juvenile, 835
poly-, 1701
psoriatic, 573, 618, 845, 1547, 1604, 1722
reactive, 458, 736, 1005, 1283, 1410, 1547
refractory, 575
septic, 1819
Spanish outcome measures, 1429
symmetric, 1701
Ureaplasma urealyticum destructive septic polyarthritis, 1524
zymosan-induced, 164
Arthritis & Rheumatism
Arend, William P., new editor, 890
editor's message, 1022
reader and author survey, 1019
Schur, Peter H., editor, in appreciation of, 743
Arthritis Foundation, future of rheumatology and, 451
Arthritis Impact Measurement Scales (AIMS), outcome measures in RA clinical trials and, 1568
Arthritis Knowledge Questionnaire, 590
Arthritis, Rheumatism and Aging Medical Information System (ARAMIS), every-other-week MTX in RA and, D24
Arthritis Self-Efficacy Scale for Pain and Other Symptoms, Spanish outcome measures and, 1429
Arthritogenesis, Yersinia enterocolitica binding of adhesin YadA to collagen and, 1283
Arthritogenic antigen, in pathogenesis of spondylarthropathies, 1547
Arthrocentesis, joint and connective tissue ultrasonography and, 736
Arthrography, in loosening of revision total hip replacement in RA, 1315
Arthropathy
chromosome Chlamydia DNA in reactive arthritis and, 1005
infectious, cytokines in JRA and, 211, 1531
iron salute as a sign of hemochromatosis, 558
Arthroplasty, total knee, proteoglycans in cartilage in OA and RA after, 660
Arthroscopy
lavage, in medical management of knee OA, 1541
needle, compartment-directed physical examination, cartilage abnormalities and, 917
rheumatologists and, 1026
Arthus reaction, IgG receptors in autoimmune disease and, 306
Articular cartilage
directed knee examination and, 917
glycosaminoglycans in knee joint fluid after trauma and, 953
human, rheumatoid synovial fibroblast adhesion in, 1694
monoclonal antibodies in detection of biochemmarkers of arthritis and, 655
in OA, 420, 525, 660
proteoglycans in, 525, 660
in RA, 660
stromelysin degradation of, 173, 1678
synovitis, protein clearance and, in canine knee, 1085
Articular chondrocytes
in aging and development, 960
matrix metalloproteinase synthesis and, 1304
nitric oxide synthase in, in pathogenesis of swelling, 1529
Articular index, Lansbury, in stromelysin-1 and TIMP-1 in RA, 969
Articular involvement, autoimmune disease induction by microbial pathogens and, 458
Ashkenazi Jewish patients, HLA-DRB1*0404 allele and, in gold-induced enterocolitis, 755
Asp, MHC class II genes, anti-U1 snRNP antibody and, 396
Asparate aminotransferase, liver biopsy after MTX in RA and, 1194
Aspiration, bone marrow fat in inflammation in sickled erythrocytes and, 1349
Aspirin, gastrointestinal tract and, 5
Assistive devices, guidelines for medical management of OA and, 1535
Atherosclerosis, cross-reactivity of anticardiolipin autoantibodies with oxidized low-density lipoprotein and, 1382
Athletes and athletics, knee OA in, 539
Atrial myxoma, in cutaneous PAN with Crohn's disease, 1161
Atrophy
cognitive deficits in rheumatic diseases and, 1363
myofiber, HTLV-1 in PM and, 690
Attention control, in stress management and clinical outcome in RA, 1807
Attitudinal factors, in work disability in RA, 1630
Autoamputation, finger, secondary to untreated gouty arthritis, 1241
Autoantibodies
anti-apolipoprotein A1 in SLE and, 1655
anti-Fcγ receptor, IgG receptors in autoimmune disease and, 306
antineutrophil cytoplasmic antibodies in mice and, 1375
autoimmune disease induction by microbial pathogens and, 458
autoimmune response to the spliceosome and, 777
clearance of, antigen-based heteropolymers and, 190
HRES-1 antibodies and, in SLE and overlap syndromes, 1660
IgG receptors in autoimmune disease and, 306
intrathecal, in Lyme borreliosis, 565
MHC class II genes, anti-U1 snRNP antibody and, 396
Mi-2 autoantigen in DM and, 123, 1389
Ro/La, 1660
in SSc, 985, 1845
Autoantigenic T cell epitope, autoimmune disease induction by microbial pathogens and, 458
Autoantigens
52-kd SS-A/Ro molecule epitopes and, 990
HRES-1, in SLE and overlap syndromes, 1660
Mi-2, in DM, 123, 1389
Autoepitopes, 52-kd SS-A/Ro, 990
``Autogenes,'' autoimmune disease induction by microbial pathogens and, 458
Autoimmune diseases
antibodies to synovial antigens in early RA and, 1418
antigen-based heteropolymers and, 190
cognitive deficits in rheumatic diseases and, 1363
HRES-1 antibodies in SLE and overlap syndromes, 1660
Autoimmune diseases (cont'd)
hydroxychloroquine, pain and, 445
immunosuppressive drugs during pregnancy and, 1722
induction of, by microbial pathogens, 458
p4 peptide binding to DRB1*0401 and, 1744
serum soluble Fas/APO-1 in, 1735
T cell receptor Vβ gene in murine Sjogren's syndrome and, 1077
understanding of, 301
``Autoimmune glandular exocrinopathy,'' cognitive deficits in rheumatic diseases and, 1363
Autoimmune lesions, T cell receptor Vβ gene in murine Sjogren's syndrome and, 1077
Autoimmune mechanisms, in Lyme borreliosis, 565
Autoimmune pancreatic islet disease, induction of, by microbial pathogens, 458
Autoimmune phenomena
autoimmune disease induction by microbial pathogens and, 458
Mi-2 autoantigen in DM and, 1389
Autoimmune process, IgG receptors in autoimmune disease and, 306
Autoimmune response
autoimmune disease induction by microbial pathogens and, 458
to spliceosome, 777
Autoimmune sialadenitis, T cell receptor Vβ gene in murine Sjogren's syndrome and, 1077
Autoimmunity
autoimmune disease and, 306, 458
in pathogenesis of spondylarthropathies, 1547
SS-A/Ro 52-kd molecule epitopes and, 990
systemic, 301
understanding of, 301, 1532
Autoimmunity-prone (New Zealand white [times] BXSB)F1 mice, cross-reactivity of anticardiolipin autoantibodies with oxidized low-density lipoprotein in, 1382
Autopsy, in fatal pulmonary vasculitis in lupus pregnancy, 710
Autoradiography
in OA, aggrecan and type II collagen genes in, 420
to study HTLV-1 in PM, 690
Autoreactivity, autoimmune disease induction by microbial pathogens and, 458
Avascular necrosis
functional disability in PM/DM and, 1218
monoclonal antibodies in detection of biochemical markers of, 655
Axial disease, in pediatric AS, 835
Axonal degeneration, in peripheral neuropathy with necrotizing vasculitis in RA, 1618
Azathioprine
cytolytic activity of polyclonal T cells in SLE and, 506
immunosuppressive drugs during pregnancy and, 1722
in RA, 142, 1799, 1851
toxicity of, 142